Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR, Ansén S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, Nadler LM. Weihrauch MR, et al. Among authors: wittig b. Clin Cancer Res. 2005 Aug 15;11(16):5993-6001. doi: 10.1158/1078-0432.CCR-05-0018. Clin Cancer Res. 2005. PMID: 16115944 Clinical Trial.
Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides.
Köchling J, König-Merediz SA, Stripecke R, Buchwald D, Korte A, Von Einsiedel HG, Sack F, Henze G, Seeger K, Wittig B, Schmidt M. Köchling J, et al. Among authors: wittig b. Clin Cancer Res. 2003 Aug 1;9(8):3142-9. Clin Cancer Res. 2003. PMID: 12912966
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.
Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, Mayer F, Andel J, Ziebermayr R, Scheithauer W. Schmoll HJ, et al. Among authors: wittig b. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. doi: 10.1007/s00432-014-1682-7. Epub 2014 May 10. J Cancer Res Clin Oncol. 2014. PMID: 24816725 Free PMC article. Clinical Trial.
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.
Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B, Zuwala K, Mack K, Olesen R, Hua S, Lichterfeld M, Østergaard L, Denton PW, Tolstrup M, Søgaard OS. Vibholm LK, et al. Among authors: wittig b. AIDS. 2019 Jul 1;33(8):1315-1325. doi: 10.1097/QAD.0000000000002213. AIDS. 2019. PMID: 30932955 Clinical Trial.
214 results